{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:07:23Z","timestamp":1791299243862,"version":"4.1.0"},"reference-count":55,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2012,11,6]],"date-time":"2012-11-06T00:00:00Z","timestamp":1352160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>There are no currently approved treatments for filovirus infections. In this study we report the discovery process which led to the development of antisense Phosphorodiamidate Morpholino Oligomers (PMOs) AVI-6002 (composed of AVI-7357 and AVI-7539) and AVI-6003 (composed of AVI-7287 and AVI-7288) targeting Ebola virus and Marburg virus respectively. The discovery process involved identification of optimal transcript binding sites for PMO based RNA-therapeutics followed by screening for effective viral gene target in mouse and guinea pig models utilizing adapted viral isolates. An evolution of chemical modifications were tested, beginning with simple Phosphorodiamidate Morpholino Oligomers (PMO) transitioning to cell penetrating peptide conjugated PMOs (PPMO) and ending with PMOplus containing a limited number of positively charged linkages in the PMO structure. The initial lead compounds were combinations of two agents targeting separate genes. In the final analysis, a single agent for treatment of each virus was selected, AVI-7537 targeting the VP24 gene of Ebola virus and AVI-7288 targeting NP of Marburg virus, and are now progressing into late stage clinical development as the optimal therapeutic candidates.<\/jats:p>","DOI":"10.3390\/v4112806","type":"journal-article","created":{"date-parts":[[2012,11,6]],"date-time":"2012-11-06T11:18:13Z","timestamp":1352200693000},"page":"2806-2830","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections"],"prefix":"10.3390","volume":"4","author":[{"given":"Patrick L.","family":"Iversen","sequence":"first","affiliation":[{"name":"Sarepta Therapeutics, Bothell, Washington 98021, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis K.","family":"Warren","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay B.","family":"Wells","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"Garza","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan V.","family":"Mourich","sequence":"additional","affiliation":[{"name":"Sarepta Therapeutics, Bothell, Washington 98021, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa S.","family":"Welch","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rekha G.","family":"Panchal","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Bavari","sequence":"additional","affiliation":[{"name":"United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2012,11,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S810","DOI":"10.1093\/infdis\/jir299","article-title":"Basic clinical and laboratory features of filoviral hemorrhagic fever","volume":"3","author":"Kortepeter","year":"2011","journal-title":"J. Infect. Dis. Suppl."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1517\/17460441.2011.554815","article-title":"Nonhuman primates as models for the discovery and development of ebolavirus therapeutics","volume":"6","author":"Shurtleff","year":"2011","journal-title":"Expert Opin. Drug Devel."},{"key":"ref_3","first-page":"135","article-title":"Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobin fom hyerimmune horses","volume":"11","author":"Jahrling","year":"1996","journal-title":"Arch. Virol. Suppl."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"20690","DOI":"10.1073\/pnas.1108360108","article-title":"Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant","volume":"108","author":"Zeitlin","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e36192","DOI":"10.1371\/journal.pone.0036192","article-title":"Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever","volume":"7","author":"Marzi","year":"2012","journal-title":"PLoS ONE"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.4049\/jimmunol.180.6.4058","article-title":"Functional CD8+ T cell responses in lethal Ebola Virus infection","volume":"180","author":"Bradfute","year":"2008","journal-title":"J Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1128\/CVI.00162-06","article-title":"A DNA vaccine for Ebola Virus is safe and immunogenic in a phase I clinical trial","volume":"13","author":"Martin","year":"2006","journal-title":"Clin. Vac. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/mt.2009.190","article-title":"Activation of transgene-specific T cells following lentivirus-mediated gene delivery to mouse lung","volume":"18","author":"Limberis","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_9","first-page":"e177","article-title":"Immune protection of nonhuman primates against Ebola Virus with single low-dose adenovirus vectors encoding modified GPs","volume":"3","author":"Sullivan","year":"2006","journal-title":"PLoS ONE"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S390","DOI":"10.1086\/520598","article-title":"Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever","volume":"15","author":"Hensley","year":"2007","journal-title":"J. Infect. Dis. Suppl."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(10)60357-1","article-title":"Postexposure protection of non-human primates against lethal Ebola virus-challenge with RNA interference: a proof-of-concept study","volume":"29","author":"Geisbert","year":"2010","journal-title":"Lancet"},{"key":"ref_12","first-page":"187","article-title":"Morpholino Antisense Oligomers: Design, Preparation and Propoerties","volume":"7","author":"Summerton","year":"1997","journal-title":"Antisense Nucleic A."},{"key":"ref_13","first-page":"235","article-title":"Phosphorodiamidate morpholino oligomers: Favorable properties for sequence-specific gene inactivation","volume":"3","author":"Iversen","year":"2001","journal-title":"Curr. Opin. Mol. Ther."},{"key":"ref_14","first-page":"267","article-title":"Resistance of Morpholino Phosphorodiamidate Oligomers to Enzymatic Degradation","volume":"6","author":"Hudziak","year":"1996","journal-title":"Antisense Nucleic A."},{"key":"ref_15","first-page":"163","article-title":"Antiproliferative Effects of Steric Blocking Phosphorodiamidate Morpholino Antisense Agents Directed Against c-myc","volume":"10","author":"Hudziak","year":"2000","journal-title":"Antisense Nucleic A."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/S0735-1097(02)01830-2","article-title":"Intramural Delivery of Advanced Antisense Oligonucleotides with Infiltrator Cathetor Inhibits c-myc Expression and Intimal Hyperplasia in the Porcine","volume":"39","author":"Kipshidze","year":"2002","journal-title":"J. Am. Col. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1046\/j.1523-1755.2002.0610s1125.x","article-title":"c-myc Antisense Oligonucleotide Treatment Ameliorates Murine Infantile Polycystic Kidney Disease","volume":"61","author":"Ricker","year":"2002","journal-title":"Kidney Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/pros.10151","article-title":"Inhibition of Human Chorionic Gonadotropin beta-Subunit Modulates the Mitogenic Effect of c-myc in Human Prostate Cancer Cells","volume":"53","author":"Devi","year":"2002","journal-title":"The Prostate"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00001813-200301000-00006","article-title":"Resistance to Chemotherapeutic Drugs Overcome by c-Myc Inhibition in Lewis Lung Carcinoma Model","volume":"14","author":"Knapp","year":"2003","journal-title":"Anti-Cancer Drug."},{"key":"ref_20","first-page":"1","article-title":"Efficacy of Antisense Morpholino Oligomer Targeted to c-myc in Prostate Cancer Xenograft Model and a Phase I Safety Study in Humans","volume":"9","author":"Iversen","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/dmd.30.7.757","article-title":"Phosphorodiamidate Morpholino Oligomers Inhibit Expression of Human Cytochrome P450 3A4 and Alter Selected Drug Metabolism","volume":"30","author":"Arora","year":"2002a","journal-title":"Drug Metab. Dispos."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1023\/A:1020448430919","article-title":"Transdermal Use of Phosphorrdiamidate Morpholino Oligomer AVI-4472 Inhibits Cytochrome P450 3A2 Activity in Male Rats","volume":"19","author":"Arora","year":"2002b","journal-title":"Pharm. Res."},{"key":"ref_23","first-page":"317","article-title":"Inhibition of Vesivirus Infetions in Mammalian Tissue Culture with Antisense Morpholino Oligomers","volume":"11","author":"Stein","year":"2001","journal-title":"Antisense Nucleic A."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2460\/ajvr.69.1.23","article-title":"Virus Specific Antiviral Therapy for Controlling Severe and Fatal Outbreaks of Feline Calicivirus Infection","volume":"69","author":"Smith","year":"2008","journal-title":"Am. J. Vet. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.0020001","article-title":"Gene-Specific Countermeasures against Ebola Virus Based on Antisense Phosphorodiamidate Morpholino Oligomers","volume":"2","author":"Warfield","year":"2006","journal-title":"PLoS Pathog."},{"key":"ref_26","first-page":"151","article-title":"A specificity comparison of four antisense types: Morpholino, 2\u2019-O-methyl RNA, DNA, and phosphorothioate DNA","volume":"7","author":"Stein","year":"1997","journal-title":"Antisense Nucleic A."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1479-0556-4-3","article-title":"Induction of revertant fibres in the mdx mouse using antisense oligonucletoides","volume":"4","author":"Fall","year":"2006","journal-title":"Genet. Vaccines Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1471-2199-8-57","article-title":"Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries","volume":"8","author":"Adams","year":"2007","journal-title":"BMC Mol. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S1474-4422(09)70211-X","article-title":"Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study","volume":"8","author":"Kinali","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(11)60756-3","article-title":"Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation stud","volume":"378","author":"Cirak","year":"2011","journal-title":"Lancet"},{"key":"ref_31","first-page":"32","article-title":"HIV Tat Peptide Enhances Cellular Delivery of Antisense Morpholino Oligomers","volume":"13","author":"Moulton","year":"2003","journal-title":"Antisense Nucleic A."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1021\/bc034221g","article-title":"Cellular Uptake of Antisense Morpholino Oligomers Conjugated to Arginine-Rich Peptides","volume":"15","author":"Moulton","year":"2004","journal-title":"BioConjugate Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jconrel.2006.09.011","article-title":"Vectorization of morpholino oligomers by the (R-Ahx-R)(4) peptide allows efficient splicing correction in the absence of endosomolytic agents","volume":"116","author":"Abes","year":"2006","journal-title":"J. Control. Release"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1021\/bc060138s","article-title":"Stability of Cell-Penetrating Peptide-Morpholino Oligomer Conjugates in Human Serum and in Cells","volume":"18","author":"Youngblood","year":"2006","journal-title":"Bioconjugate Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1093\/nar\/gkm478","article-title":"Cell-Penetrating Peptides as Transporters for Morpholino Oligomers: Effects of Amino Acid Composition on Intracellular Delivery and Cytotoxicity","volume":"35","author":"Wu","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jim.2007.06.009","article-title":"Arginine-rich cell penetrating peptides facilitate delivery of antisense oligomers into murine leukocytesand alter pre-mRNA splicing","volume":"325","author":"Marshall","year":"2007","journal-title":"J. Immunology Methods"},{"key":"ref_37","first-page":"95","article-title":"Cell penetrating peptide conjugates of steric block oligonucleotides","volume":"77","author":"Lebleu","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1128\/AAC.47.10.3233-3239.2003","article-title":"Inhibition of Gene Expression in Escherichia coli by Antisense Phosphorodiamidate Morpholino Oligomers","volume":"47","author":"Geller","year":"2003","journal-title":"Antimicrob. Agents Ch."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1128\/AAC.49.1.249-255.2005","article-title":"Antisense phosphorodiamidate morpholino oligomer length and target position effects on gene-specific inhibition in Escherichia coli","volume":"49","author":"Deere","year":"2005","journal-title":"Antimicrob. Agents Ch."},{"key":"ref_40","first-page":"1093","article-title":"Antisense phosphorodiamidate morpholino oligomer inhibits viability of Escherichia coli in pure culture and in mouse peritonitis","volume":"10","author":"Geller","year":"2005","journal-title":"J. Antimicrob. Chemoth."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/jac\/dkl444","article-title":"Antisense peptide-phosphorodiamidate morpholino oligmer conjugate: dose-response in mice infected with Escherichia coli","volume":"59","author":"Tilley","year":"2007","journal-title":"J. Antimicrob. Chemoth."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1128\/AAC.00917-08","article-title":"Variations in amino acid composition of antisense peptide-phosphorodiamidate Morpholino oligomer affect potency in vitro and in vivo","volume":"53","author":"Mellbye","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1086\/652807","article-title":"Antisense phosphorodiamidate morpholino oligomers targeted to an essential gene inhibit Burkholderia cepacia complex","volume":"201","author":"Greenberg","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1128\/AAC.01286-05","article-title":"Gene-Specific Effects of Antisense Phosphorodiamidate Morpholino Oligomer-Peptide Conjugates on Escherichia coli and Salmonella enterica Serovar Typhimurium in Pure Culture and in Tissue Culture","volume":"50","author":"Tilley","year":"2006","journal-title":"Antimicrob. Agents Ch."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1128\/AAC.00099-09","article-title":"Inhibition of Intracellular Growth of Salmonella enterica serovar typhimurium in Tissue Culture by Antisense Peptide-Phosphorodiamidate Morpholino Oligomer","volume":"53","author":"Mitev","year":"2009","journal-title":"Antimicrob. Agents Ch."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1128\/AAC.50.3.984-993.2006","article-title":"VP35 Knockdown Inhibits Ebola Virus Amplification and Protects against Lethal Infection in Mice","volume":"50","author":"Enterlein","year":"2006","journal-title":"Antimicr. Agents Ch."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1128\/AAC.00936-08","article-title":"Chemical modifications to phosphorodiamidate Morpholino oligomer antisense molecules targeting VP24 modify their efficacy against Ebola virus infection","volume":"53","author":"Swenson","year":"2009","journal-title":"Antimicrob Agents Ch."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"11510","DOI":"10.1128\/JVI.00900-06","article-title":"Inhibition of coxsackievirus b3 in cell cultures and in mice by Peptide-conjugated morpholino oligomers targeting the internal ribosomal entry site","volume":"80","author":"Yuan","year":"2006","journal-title":"J. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1099\/vir.0.83449-0","article-title":"Morpholino Oligomers Targeting the PB1 and NP Genes Enhance Survival of Mice Infected with highly Pathogenic Influenza A H7N7 Virus","volume":"89","author":"Gabriel","year":"2008","journal-title":"J. Gen. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s00705-008-0067-0","article-title":"Inhibition of influenza A H3N8 virus infections in mice by morpholino oligomers","volume":"153","author":"Lupfer","year":"2008","journal-title":"Arch. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.virol.2008.03.032","article-title":"Inhibition of alphavirus infection in cell culture and in mice with antisense morpholino oliogmers","volume":"5","author":"Paessler","year":"2008","journal-title":"Virology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1128\/AAC.00011-08","article-title":"Inhibition of multiple species of picornavirus using a morpholino oligomer targeting highly conserved IRES sequence","volume":"52","author":"Stone","year":"2008","journal-title":"Antimicrob Agents Ch."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Warren, T.K., Warfield, K.L., Wells, J., Swenson, D.L., Donner, K.S., Van Tongeren, S.A., Garza, N.L., Dong, L., Mourich, D.V., Crumley, S., Nichols, D.K., Iversen, P.L., and Bavari, S. (2010). Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat. Med., 991\u2013994.","DOI":"10.1038\/nm.2202"},{"key":"ref_54","first-page":"163","article-title":"Antiproliferative Effects of Steric Blocking Phosphorodiamidate Morpholino Antisense Agents Directed Against c-myc","volume":"10","author":"Hudziak","year":"2000","journal-title":"Antisense Nucleic A."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/jac\/dkn221","article-title":"Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus","volume":"62","author":"Stein","year":"2008","journal-title":"J. Antimicrob. Ch."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/4\/11\/2806\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:53:21Z","timestamp":1760219601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/4\/11\/2806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,6]]},"references-count":55,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2012,11]]}},"alternative-id":["v4112806"],"URL":"https:\/\/doi.org\/10.3390\/v4112806","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,6]]}}}